Microbicides Acceptability Among Sexually Active Young Women
27. februar 2017 opdateret af: University of North Carolina, Chapel Hill
Microbicide-Use Adherence, Acceptability, and Attitudes Among Sexually Active Young Women Participating in a Phase I Microbicide Trial (MTN 004) "Tell Juliana"
ATN 062 is designed to gain scientific knowledge of microbicide-use adherence, acceptability, and attitudes among sexually active young women
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
ATN 062 will take place in parallel to another study, MTN 004, "Phase I Study of the Safety and Acceptability of 3% w/w SPL7013 Gel (VivaGel™) Applied Vaginally in Sexually Active Young Women."
ATN 062 will use quantitative and qualitative research methods.
The quantitative method will consist of a computerized diary used by participants during the 14 days of the gel trial of MTN 004.
The qualitative methods will include email messages sent by participants to a research assistant as a supplement to the diaries, as well as in-depth interviews through teleconferences to contextualize the recorded events.
All study activities will be timed to coincide with those of MTN 004
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
59
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33606
- University of South Florida College of Medicine
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- University of Pittsburgh Medical Center
-
-
-
-
-
San Juan, Puerto Rico, 00936
- University Pediatric Hospital
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 24 år (Voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Kvinde
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
HIV-negative women ages 18 to 24 years old who are non-pregnant, sexually active and enrolled in MTN 004 will be offered the option to enroll in ATN 062.
Approximately half of the participants will be recruited in San Juan, PR, and the other half in Tampa, FL.
Beskrivelse
Inclusion Criteria:
- Currently enrolled in MTN 004.
- Willing and able to provide written informed consent for ATN 062.
- Willing to participate as required by protocol, including completion of all assessments and follow-ups.
Exclusion Criteria:
- Refuses to have teleconferences audio recorded.
- Any social or medical condition that, in the investigator's opinion, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Kohorte
- Tidsperspektiver: Fremadrettet
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
1
Participants use Vivagel™, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
|
Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial.
They will have three teleconferences with "Juliana" to discuss the product and the technology used in the study.
They will also have the opportunity to send emails to "Juliana" during the course of the study.
Andre navne:
|
|
2
Participants use VivaGel™ Placebo, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
|
Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial.
They will have three teleconferences with "Juliana" to discuss the product and the technology used in the study.
They will also have the opportunity to send emails to "Juliana" during the course of the study.
Andre navne:
|
|
3
Participants use HEC Placebo Gel (HEC Gel), applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
|
Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial.
They will have three teleconferences with "Juliana" to discuss the product and the technology used in the study.
They will also have the opportunity to send emails to "Juliana" during the course of the study.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Microbicide use adherence as measured by a computerized phone diary
Tidsramme: 21 days(through end of study)
|
21 days(through end of study)
|
|
Microbicide use adherence as measured by e-mail messages
Tidsramme: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use adherence as measured by in-depth interviews via teleconference
Tidsramme: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use acceptability as measured by a computerized phone diary
Tidsramme: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use acceptability as measured by e-mail messages
Tidsramme: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use acceptability as measured by in-depth interviews via teleconferences
Tidsramme: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use attitudes as measured by a computerized phone diary
Tidsramme: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use attitudes as measured by e-mail messages
Tidsramme: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use attitudes as measured by in-depth interviews via teleconferences
Tidsramme: 21 days (through end of study)
|
21 days (through end of study)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Efterforskere
- Studiestol: Alex Carballo-Diéguez, PhD, HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. august 2007
Primær færdiggørelse (Faktiske)
1. november 2009
Studieafslutning (Faktiske)
1. november 2009
Datoer for studieregistrering
Først indsendt
21. juni 2007
Først indsendt, der opfyldte QC-kriterier
21. juni 2007
Først opslået (Skøn)
22. juni 2007
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
28. februar 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
27. februar 2017
Sidst verificeret
1. maj 2016
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ATN 062
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .